Segment Reporting – Corporate and Other/Merck Group

XLS

 

 

 

 

 

 

Corporate and Other

Merck Group

EUR million

Q1
2011

Q1
2010

Q1
2011

Q1
2010

*

Reporting period ending on March 31, 2011. The previous year’s figures as of December 31, 2010.

Sales

2,477.5

2,022.8

Royalty, license and commission income

86.2

76.1

Total revenues

2,563.8

2,098.9

Gross margin

1,924.1

1,612.2

Marketing and selling expenses

–0.5

–1.1

–591.6

–468.2

Royalty, license and commission expenses

–111.3

–122.2

Administration expenses

–19.5

–16.3

–124.9

–104.4

Other operating expenses and income

–5.3

–34.2

–97.1

–134.9

Research and development

0.1

–379.5

–347.2

Operating result

–25.3

–51.5

371.6

294.8

Exceptional items

158.0

Earnings before interest and tax (EBIT)

–25.3

–51.5

529.5

294.8

Net operating assets*

66.8

74.7

17,856.6

18,470.5

Segment liabilities*

–11.7

–14.9

–1,787.9

–1,898.4

Capital spending on property, plant and equipment

0.1

0.1

74.9

64.7

Investments in intangible assets

2.4

0.9

9.3

14.0

Depreciation and amortization

–1.5

–0.6

–302.5

–220.2

Impairment losses

–50.4

–26.2

Net cash flows from operating activities

252.1

–111.8

284.9

278.7

Net cash flows from investing activities

259.9

1,344.8

104.3

1,269.5

Free cash flow

255.9

–120.4

645.3

194.8

Underlying free cash flow

255.9

–108.6

185.6

206.6

FCR in %

7.2

9.8

ROS in %

14.5

14.0